See more : Super Telecom Co.,Ltd (603322.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Teligent, Inc. (TLGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Teligent, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Public Joint Stock Company Moscow City Telephone Network (MGTS.ME) Income Statement Analysis – Financial Results
- Morepen Laboratories Limited (MOREPENLAB.BO) Income Statement Analysis – Financial Results
- Kurita Water Industries Ltd. (6370.T) Income Statement Analysis – Financial Results
- Bank of Suzhou Co., Ltd. (002966.SZ) Income Statement Analysis – Financial Results
- Pantheon International PLC (PIN.L) Income Statement Analysis – Financial Results
Teligent, Inc. (TLGT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.teligent.com
About Teligent, Inc.
Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.
| Metric | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.31M | 65.90M | 67.25M | 66.88M | 44.25M | 33.74M | 18.22M | 8.56M | 7.81M | 6.09M | 3.78M | 4.07M | 4.58M | 2.62M | 2.87M | 3.56M | 3.56M | 4.36M | 15.90M | 19.25M | 34.59M | 33.20M | 34.20M | 35.10M | 31.20M | 28.90M | 28.00M | 24.40M | 22.00M | 20.10M | 18.30M | 16.00M | 15.70M | 18.40M | 17.80M |
| Cost of Revenue | 0.00 | 42.37M | 39.88M | 32.19M | 22.94M | 16.95M | 12.08M | 5.79M | 5.55M | 4.99M | 3.53M | 2.85M | 2.48M | 1.39M | 1.92M | 1.25M | 1.35M | 1.38M | 8.77M | 9.19M | 16.46M | 16.00M | 16.80M | 15.10M | 14.60M | 13.10M | 12.20M | 10.20M | 9.70M | 8.70M | 8.00M | 7.00M | 6.80M | 7.90M | 8.50M |
| Gross Profit | 45.31M | 23.52M | 27.37M | 34.69M | 21.32M | 16.79M | 6.15M | 2.78M | 2.26M | 1.11M | 251.00K | 1.22M | 2.11M | 1.23M | 947.00K | 2.31M | 2.21M | 2.99M | 7.13M | 10.06M | 18.14M | 17.20M | 17.40M | 20.00M | 16.60M | 15.80M | 15.80M | 14.20M | 12.30M | 11.40M | 10.30M | 9.00M | 8.90M | 10.50M | 9.30M |
| Gross Profit Ratio | 100.00% | 35.70% | 40.70% | 51.86% | 48.17% | 49.77% | 33.72% | 32.42% | 28.95% | 18.13% | 6.64% | 29.93% | 45.95% | 47.02% | 33.03% | 64.78% | 62.19% | 68.42% | 44.85% | 52.24% | 52.43% | 51.81% | 50.88% | 56.98% | 53.21% | 54.67% | 56.43% | 58.20% | 55.91% | 56.72% | 56.28% | 56.25% | 56.69% | 57.07% | 52.25% |
| Research & Development | 548.00K | 10.76M | 19.27M | 17.14M | 13.17M | 6.91M | 2.74M | 2.83M | 2.15M | 1.51M | 740.00K | 502.00K | 481.00K | 1.07M | 949.00K | 1.73M | 762.00K | 549.00K | 536.00K | 853.00K | 1.42M | 1.40M | 1.70M | 2.00M | 1.30M | 800.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33M | 7.99M | 14.06M | 15.70M | 15.00M | 15.00M | 11.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33M | 7.99M | 14.06M | 15.70M | 15.00M | 15.00M | 11.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 20.79M | 19.90M | 15.01M | 11.34M | 5.98M | 3.48M | 3.08M | 3.08M | 3.23M | 3.60M | 2.78M | 2.43M | 2.11M | 1.68M | 1.80M | 2.42M | 2.36M | 1.42M | 1.37M | 1.15M | 1.00M | 1.00M | 1.00M | 800.00K | 11.50M | 12.50M | 13.80M | 11.70M | 10.40M | 9.60M | 8.10M | 7.50M | 7.90M | 8.40M |
| Operating Expenses | 548.00K | 31.54M | 39.17M | 32.15M | 24.51M | 12.89M | 6.23M | 5.91M | 5.23M | 4.74M | 4.34M | 3.28M | 2.91M | 3.17M | 2.63M | 3.53M | 3.18M | 2.91M | 7.29M | 10.22M | 16.63M | 18.10M | 17.70M | 18.00M | 14.00M | 12.30M | 12.50M | 13.80M | 11.70M | 10.40M | 9.60M | 8.10M | 7.50M | 7.90M | 8.40M |
| Cost & Expenses | 548.00K | 73.92M | 79.05M | 64.34M | 47.44M | 29.83M | 18.31M | 11.70M | 10.78M | 9.73M | 7.87M | 6.13M | 5.39M | 4.56M | 4.55M | 4.78M | 4.53M | 4.29M | 16.06M | 19.41M | 33.09M | 34.10M | 34.50M | 33.10M | 28.60M | 25.40M | 24.70M | 24.00M | 21.40M | 19.10M | 17.60M | 15.10M | 14.30M | 15.80M | 16.90M |
| Interest Income | 0.00 | -21.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -962.00K | 17.00K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.00K | 7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.61M | 0.00 | 0.00 | 0.00 | 0.00 | 13.00K | 281.00K | 13.00K | 938.00K | 0.00 | 48.00K | 129.00K | 4.00K | 0.00 | 0.00 | 283.00K | 2.13M | 2.75M | 0.00 | 3.40M | 0.00 | 2.00M | 1.30M | 1.00M | 600.00K | 700.00K | 600.00K | 800.00K | 700.00K | 500.00K | 0.00 | 800.00K | 1.00M |
| Depreciation & Amortization | 6.55M | 6.70M | 4.64M | 3.78M | 1.17M | 515.00K | 475.00K | 457.00K | 419.00K | 376.00K | 348.00K | 349.00K | 336.00K | 371.00K | 300.00K | 271.00K | 269.00K | 581.00K | 1.03M | 1.37M | 1.15M | 1.00M | 1.00M | 1.00M | 800.00K | 800.00K | 1.00M | 1.10M | 900.00K | 700.00K | 700.00K | 600.00K | 600.00K | 700.00K | 900.00K |
| EBITDA | 48.60M | -18.34M | -9.02M | -7.92M | 7.88M | 5.94M | 194.00K | -3.64M | -2.53M | -3.25M | -3.74M | -1.70M | -401.00K | -1.63M | -1.27M | -911.00K | -261.00K | 9.97M | 1.15M | -10.22M | -1.04M | 100.00K | -1.10M | 3.00M | 200.00K | 2.70M | -1.60M | 1.80M | 1.60M | 1.70M | 1.40M | 1.40M | 2.10M | 2.90M | 1.10M |
| EBITDA Ratio | 107.27% | -27.83% | -13.42% | -11.84% | 17.80% | 17.60% | 1.06% | -42.52% | -32.45% | -53.35% | -99.05% | -41.75% | -8.75% | -62.02% | -44.40% | -25.60% | -7.34% | 228.55% | 7.22% | -53.10% | -2.99% | 0.30% | -3.22% | 8.55% | 0.64% | 9.34% | -5.71% | 7.38% | 7.27% | 8.46% | 7.65% | 8.75% | 13.38% | 15.76% | 6.18% |
| Operating Income | 44.76M | -8.02M | -11.80M | 2.54M | -3.19M | 3.91M | -82.00K | -3.14M | -2.97M | -3.63M | -4.09M | -2.06M | -806.00K | -1.94M | -1.68M | -1.22M | -972.00K | 79.00K | -161.00K | -157.00K | 1.51M | -900.00K | -300.00K | 2.00M | 2.60M | 3.50M | 3.30M | 400.00K | 600.00K | 1.00M | 700.00K | 900.00K | 1.40M | 2.60M | 900.00K |
| Operating Income Ratio | 98.79% | -12.17% | -17.54% | 3.80% | -7.21% | 11.58% | -0.45% | -36.62% | -38.03% | -59.58% | -108.28% | -50.65% | -17.59% | -73.97% | -58.60% | -34.29% | -27.33% | 1.81% | -1.01% | -0.82% | 4.35% | -2.71% | -0.88% | 5.70% | 8.33% | 12.11% | 11.79% | 1.64% | 2.73% | 4.98% | 3.83% | 5.63% | 8.92% | 14.13% | 5.06% |
| Total Other Income/Expenses | 548.00K | -17.01M | -3.48M | -14.24M | 9.90M | 1.52M | -199.00K | -975.00K | -264.00K | -9.00K | -937.00K | 13.00K | 16.00K | -129.00K | 103.00K | 38.00K | 7.00K | -225.00K | -2.13M | -2.75M | -4.08M | -3.40M | -1.80M | 0.00 | -500.00K | -900.00K | -600.00K | 200.00K | 0.00 | -1.10M | 0.00 | 0.00 | 100.00K | -1.00M | -1.00M |
| Income Before Tax | 45.31M | -25.03M | -15.28M | -11.70M | 6.70M | 5.42M | -281.00K | -4.11M | -3.23M | -3.64M | -5.03M | -2.05M | -790.00K | -2.07M | -1.58M | -1.18M | -965.00K | -146.00K | -2.29M | -2.91M | -2.57M | -4.30M | -2.10M | 0.00 | 2.10M | 2.60M | 2.70M | 600.00K | 0.00 | -100.00K | 0.00 | 0.00 | 1.50M | 1.60M | -100.00K |
| Income Before Tax Ratio | 100.00% | -37.99% | -22.71% | -17.49% | 15.15% | 16.08% | -1.54% | -48.01% | -41.42% | -59.73% | -133.09% | -50.33% | -17.25% | -78.89% | -55.01% | -33.22% | -27.13% | -3.35% | -14.43% | -15.12% | -7.43% | -12.95% | -6.14% | 0.00% | 6.73% | 9.00% | 9.64% | 2.46% | 0.00% | -0.50% | 0.00% | 0.00% | 9.55% | 8.70% | -0.56% |
| Income Tax Expense | 45.31M | 91.00K | -85.00K | 287.00K | 35.00K | 173.00K | -197.00K | -184.00K | -226.00K | -217.00K | -108.00K | -196.00K | -453.00K | -458.00K | -279.00K | -290.00K | -208.00K | 330.00K | -271.00K | 5.86M | -601.00K | -1.30M | -600.00K | -100.00K | 600.00K | 600.00K | 900.00K | -100.00K | 600.00K | -200.00K | 0.00 | 500.00K | 700.00K | 1.00M | 500.00K |
| Net Income | 0.00 | -25.12M | -15.19M | -11.99M | 6.67M | 5.25M | -84.00K | -3.93M | -3.01M | -3.42M | -4.92M | -1.85M | -332.00K | -1.67M | -1.30M | -892.00K | -322.00K | 8.78M | -1.74M | -20.21M | -1.58M | -3.00M | -1.50M | 100.00K | -2.50M | 300.00K | -4.10M | 100.00K | 100.00K | 100.00K | 0.00 | 300.00K | 800.00K | 400.00K | -1.30M |
| Net Income Ratio | 0.00% | -38.13% | -22.59% | -17.92% | 15.07% | 15.56% | -0.46% | -45.86% | -38.52% | -56.17% | -130.23% | -45.51% | -7.25% | -63.63% | -45.27% | -25.07% | -9.05% | 201.19% | -10.94% | -104.99% | -4.58% | -9.04% | -4.39% | 0.28% | -8.01% | 1.04% | -14.64% | 0.41% | 0.45% | 0.50% | 0.00% | 1.88% | 5.10% | 2.17% | -7.30% |
| EPS | 0.00 | -4.67 | -2.85 | -2.26 | 1.26 | 1.05 | -0.02 | -0.99 | -0.76 | -2.30 | -3.31 | -1.24 | -0.23 | -1.30 | -1.08 | -0.77 | -0.28 | 7.68 | -1.59 | -19.81 | -1.65 | -3.17 | -1.59 | 0.10 | -2.57 | 0.30 | -4.90 | 0.10 | 0.10 | 0.20 | 0.00 | 0.30 | 1.00 | 0.60 | -1.80 |
| EPS Diluted | 0.00 | -4.67 | -2.85 | -2.26 | 0.99 | 0.82 | -0.02 | -0.99 | -0.76 | -2.30 | -3.31 | -1.24 | -0.23 | -1.30 | -1.08 | -0.74 | -0.28 | 7.68 | -1.59 | -19.81 | -1.58 | -3.17 | -1.59 | 0.10 | -2.50 | 0.30 | -4.60 | 0.10 | 0.10 | 0.20 | 0.00 | 0.30 | 1.00 | 0.60 | -1.80 |
| Weighted Avg Shares Out | 77.14M | 5.38M | 5.33M | 5.31M | 5.29M | 4.98M | 3.98M | 3.98M | 3.94M | 1.49M | 1.49M | 1.49M | 1.43M | 1.28M | 1.20M | 1.15M | 1.14M | 1.14M | 1.10M | 1.02M | 960.48K | 947.04K | 945.79K | 1.00M | 972.52K | 1.00M | 836.74K | 1.00M | 1.00M | 500.00K | 666.67K | 1.00M | 800.00K | 666.67K | 722.22K |
| Weighted Avg Shares Out (Dil) | 77.14M | 5.38M | 5.33M | 5.31M | 6.71M | 6.42M | 3.98M | 3.98M | 3.94M | 1.49M | 1.49M | 1.49M | 1.43M | 1.28M | 1.20M | 1.20M | 1.15M | 1.14M | 1.10M | 1.02M | 1.00M | 947.04K | 945.79K | 1.00M | 1.00M | 1.00M | 891.30K | 1.00M | 1.00M | 500.00K | 666.67K | 1.00M | 800.00K | 666.67K | 722.22K |
TLGT Stock: Why The Price Substantially Fell
The stock price of Teligent Inc (NASDAQ: TLGT) fell over 39% yesterday. This is why it happened.
Top Penny Stocks to Buy Right Now? 3 to Check Out This Month
Are these top penny stocks to watch on your list in September? The post Top Penny Stocks to Buy Right Now?
Teligent, Inc. (TLGT) CEO Tim Sawyer on Q2 2021 Results - Earnings Call Transcript
Teligent, Inc. (TLGT) CEO Tim Sawyer on Q2 2021 Results - Earnings Call Transcript
Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update
BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update.
Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders
Scheduled to Reconvene on June 30, 2021 Company Urgently Encourages Stockholders to Vote
Trading Biotech Penny Stocks? Check These 3 Out
Biotech penny stocks are heating up as Covid cases decline; which small-caps are on your watchlist? The post Trading Biotech Penny Stocks?
Teligent's (TLGT) CEO Tim Sawyer on Q1 2021 Results - Earnings Call Transcript
Teligent's (TLGT) CEO Tim Sawyer on Q1 2021 Results - Earnings Call Transcript
Teligent: Q1 Earnings Insights
Shares of Teligent (NASDAQ:TLGT) rose 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 13.04% year over year to ($0.26), which may not compare to the estimate of ($2.11).
Teligent, Inc. to Hold Conference Call for First Quarter 2021 Financial Results on Tuesday May 25, 2020
BUENA, N.J., May 21, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Tuesday, May 25th, 2021 to discuss the first quarter ended March...
Teligent, Inc. Announces 2020 Year-End Earnings Report and Provides Business Update
BUENA, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2020.
Source: https://incomestatements.info
Category: Stock Reports